Category: Allies & Partnerships
UV4Me Reaches Young Adults About Sun Safety
By Cody R. Barnett, MRA Director of Communications | 1 February 2019 In Allies & Partnerships, Prevention
Among young people, rates of melanoma are especially alarming. It is now the second most-common cancer among young women aged 20 – 29. While many programs focus specifically on children, studies suggest that we receive over half of our lifetime exposure to UV after the age of 20. Yet, few evidence-based programs focus specifically on the needs of young adults.
Make Your Sun Safety Habit Stick: La Roche Posay’s My Skin Track UV
By Cody R. Barnett, MRA Director of Communications | 3 January 2019 In Allies & Partnerships, Prevention
Last month’s arrival of La Roche Posay’s My Skin Track UV may be just what the doctor ordered to help people understand the danger of overexposure to ultraviolet radiation.
Health Literacy Month: How to Ask Your Doctor about Melanoma Clinical Trials
10 October 2018 In Allies & Partnerships, Treatment
If you’ve ever had a hard time understanding your doctor or following directions on a medicine bottle, you’re definitely not alone. Understanding health information is a challenge for at least 90 million Americans today. In honor of Health Literacy Month, we highlighted some of the ways patients can be feel empowered to ask questions and access better care.
Are you #SunSavvy365?
By Cody R. Barnett, MRA Director of Communications | 4 September 2018 In Allies & Partnerships, Prevention
It’s easy to think of sunscreen when you are lounging by a pool, but did you know that it’s important to protect yourself and those you love every day of the year? That’s why MRA partnered with the Melanoma Action Coalition to create #SunSavvy365, a social media campaign that reminds us to protect our skin whether we are making sand castles or snowmen.
Uveal ‘Clusters’ in Auburn, AL and Huntersville, NC
By Cody R. Barnett, MRA Director of Communications | 18 July 2018 In Allies & Partnerships, Melanoma Stories, News, Science, Treatment
When we talk about melanoma, it’s easy to forget that cutaneous – the most common variety that forms on the skin – isn’t the only game in town. Uveal represents about 5% of all melanomas diagnosed each year. So, when dozens of people from two towns in North Carolina and Alabama were diagnosed with the rare cancer alarm bells sounded.
Join the Ready. Raise. Rise. Pic Your Power Challenge!
20 June 2018 In Allies & Partnerships
We're thrilled to let you know that we are participating in Ready. Raise. Rise., a campaign sponsored by Bristol-Myers Squibb to raise awareness of immunotherapy (sometimes called immuno-oncology) research, including the emerging area of biomarkers. This year, Ready. Raise. Rise. is introducing the Pic Your Power challenge and we hope that you'll take part!
We’ve Teamed Up with the American Cancer Society
By Cody R. Barnett, MRA Director of Communications | 7 June 2018 In Allies & Partnerships, Science, Treatment
American Cancer Society and Melanoma Research Alliance have united to fund lifesaving research aimed at reducing side effects and improving outcomes for patients treated with immunotherapy.
American Cancer Society and Melanoma Research Alliance Fund Five Innovative Approaches to Reduce Immunotherapy Side Effects
10 May 2018 In Allies & Partnerships, Science
As the world marks Melanoma Awareness Month, the American Cancer Society (ACS) and the Melanoma Research Alliance (MRA) selected the first group of scientists to receive newly established research grants to investigate how to reduce rare, but serious, side effects resulting from cancer treatments with checkpoint inhibitors, a type of immunotherapy.
Take the Skin Check Pledge
By Cody R. Barnett, MRA Director of Communications | 30 April 2018 In Allies & Partnerships, Prevention
MRA and L'Oréal Paris challenge you to take the Skin Check Pledge.For each person who takes the skin check pledge, L'Oréal Paris has committed $100 per sign up, up to $250,000 for 2018. L'Oréal Paris is a featured partner of the Melanoma Research Alliance, committed to supporting research.
Are Personalized Vaccines Part of a New Combination Approach to Treating Melanoma?
By Cody R. Barnett, MRA Director of Communications | 29 April 2018 In Allies & Partnerships, Science
Bracing for cold weather and the threat of runny noses and sore throats, millions of Americans are vaccinated for the flu each year. By priming the immune system, the vaccine reduces the risk of catching the flu and, if not successful at preventing it altogether, reduces both the severity and the duration of symptoms. These are ‘one-size-fits-all’ vaccines that are useful for all people. But what if each and every person’s flu, like each person’s melanoma, was unique? You’d need a personalized vaccine that was made and customized for each individual. Dr. Patrick Ott, Clinical Director of the Melanoma Center at the Dana-Farber Cancer Institute and lead researcher on the BJ's Wholesale Club-MRA Team Science Award, is conducting pioneering research to harness the power of personalized vaccines to combat melanoma.